Drug Profile
QAX 028
Alternative Names: QAX028Latest Information Update: 02 Nov 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiasthmatics; Bronchodilators
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 31 Aug 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in European Union (Inhalation)
- 31 Aug 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA (Inhalation)
- 25 Aug 2010 Novartis completes a phase II trial (NCT01068613) in Chronic obstructive pulmonary disease in USA